Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nivolumab - Bristol-Myers Squibb/Ono Pharmaceuticals

Drug Profile

Nivolumab - Bristol-Myers Squibb/Ono Pharmaceuticals

Alternative Names: BMS-936558; BMS-936558-01; MDX-1106; NIVO; Nivolumab BMS; ono-0123; ONO-4538; Opdivo

Latest Information Update: 29 Jul 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medarex; Ono Pharmaceutical
  • Developer Aduro BioTech; Agios Pharmaceuticals; AIO Studien gGmbH; Alliance Foundation Trials; Australian and New Zealand Urogenital and Prostate Cancer Group; Barbara Ann Karmanos Cancer Institute; Bavarian Nordic; Big Ten Cancer Research Consortium; Bristol-Myers Squibb; Calithera Biosciences; Canadian Cancer Trials Group; Celleron Therapeutics; Clatterbridge Cancer Centre NHS Foundation Trust; Clovis Oncology; Compugen; Curie Institute; Daiichi Sankyo Company; Dana-Farber Cancer Institute; Eisai Inc; Eli Lilly and Company; Emory University; European Thoracic Oncology Platform; Exelixis; F-star Therapeutics; Frontier Science foundation; Grupo Espanol Multidisciplinar de Melanoma; H. Lee Moffitt Cancer Center and Research Institute; Hoosier Cancer Research Network; HOVON Foundation; Icahn School of Medicine at Mount Sinai; Incyte Corporation; Intergroupe Francophone de Cancerologie Thoracique; Janssen Biotech; Janssen Research & Development; Kansai Medical University; Kyoto Breast Cancer Research Network; M. D. Anderson Cancer Center; Massachusetts General Hospital; Medarex; Memorial Sloan-Kettering Cancer Center; Nantes University Hospital; National Cancer Center (Tokyo); National Cancer Centre (Singapore); National Cancer Institute (USA); Nektar Therapeutics; Neon Therapeutics; Netherlands Cancer Institute; Northwestern University; Novartis; Ono Pharmaceutical; Pharmacyclics; PrECOG; Seagen; Sidney Kimmel Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Syneos Health; TARIS Biomedical; The University of Montreal Hospital Research Center; UNICANCER; University College London; University of Liverpool; University of Pittsburgh Medical Center; University of Texas M. D. Anderson Cancer Center; Vanderbilt-Ingram Cancer Center; Zucero Therapeutics
  • Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma; Malignant melanoma; Gastric cancer; Liver cancer; Hodgkin's disease; Oesophageal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Gastric cancer; Head and neck cancer; Hodgkin's disease; Liver cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer
  • Registered Oesophageal cancer; Small cell lung cancer
  • Phase III Bladder cancer; Breast cancer; Fallopian tube cancer; Glioblastoma; Multiple myeloma; Ovarian cancer; Peritoneal cancer; Prostate cancer; Squamous cell cancer
  • Phase II/III Non-Hodgkin's lymphoma
  • Phase II Acute myeloid leukaemia; Adrenocortical carcinoma; Alveolar soft part sarcoma; Biliary cancer; Brain metastases; Bronchopulmonary dysplasia; Cancer; Cervical cancer; Cholangiocarcinoma; Chronic lymphocytic leukaemia; Clear cell sarcoma; CNS cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Genitourinary disorders; Glioma; Leucoplakia; Liver metastases; Meningeal carcinomatosis; Myelodysplastic syndromes; Nasopharyngeal cancer; Pancreatic cancer; Penile cancer; Peripheral T-cell lymphoma; Soft tissue sarcoma; Solid tumours; Testicular cancer; Thyroid cancer; Uterine cancer; Uveal melanoma
  • Phase I/II Haematological malignancies; Lymphoma; Rectal cancer
  • Phase I Autoimmune disorders; Neurofibromatosis 1; Plexiform neurofibroma
  • No development reported Chronic myeloid leukaemia; Hepatitis C; Sepsis

Most Recent Events

  • 27 Jul 2021 BridgeBio Pharma and Bristol Myers Squibb enter into a clinical collaboration for solid tumours
  • 27 Jul 2021 BridgeBio Pharma and Bristol Myers Squibb plan phase I/II trial for Non-small cell lung cancer (Combination therapy, First-line therapy) in USA
  • 27 Jul 2021 BridgeBio Pharma and Bristol Myers Squibb plan phase I/II trial for Non-small cell lung cancer (Combination therapy, Second-line therapy or greater) in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top